An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo
Source : https://www.sciencedirect.com/science/article/abs/pii/S0304383521006583?via=ihub
WK500B exhibits potent efficacy against DLBCL in vitro and in vivo. * WK500B shows favourable pharmacokinetic and presents superior druggability. * WK500B could be a promising therapeutic drug candidate for...
Conclusion/Relevance: WK500B is a promising candidate that could be developed as an effective orally available therapeutic agent for DLBCL.
Clinical Features and Prognostic Significance of NOTCH1 Mutations in Diffuse Large B-Cell Lymphoma
Source : https://www.frontiersin.org/articles/10.3389/fonc.2021.746577/full
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of large lymphoid B cell malignancy with distinct clinical and genetic features. Recently, NOTCH1 mutations were identified in DLBCL cases by...
Conclusion/Relevance: In conclusion, DLBCL patients with the NOTCH1 mutations have worse PFS and OS, and the NOTCH1 mutations can be used as an independent predictor for patients with DLBCL.
Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34969327/
doi: 10.1080/10428194.2021.2020782. Online ahead of print. 1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2 Department of Translational Molecular Pathology, The...
Conclusion/Relevance: The beneficial effect of statins on the anti-lymphoma activity of the rituximab-based chemotherapy regimen is controversial. Here, we retrospectively reviewed patients with naïve-treated advanced diffuse large B-cell lymphoma (DLBCL) receiving frontline R-CHOP, and for whom data regarding differential statins use was...
Construction and validation of a risk scoring model for diffuse large B-cell lymphoma based on ferroptosis-related genes and its association with immune infiltration - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34920339/
doi: 10.1016/j.tranon.2021.101314. Online ahead of print. 1 Departments of Hematology, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong 528300, China. Electronic address: [email protected]. 2 Department...
Conclusions: In this study, a ferroptosis-based risk scoring model for patients with DLBCL was constructed and validated in an independent dataset. This risk score model has a better efficacy in predicting survival compared to clinical characteristics.
Double-hit lymphoma: optimizing therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34889402/
Aggressive B-cell lymphoma is a heterogeneous entity with disparate outcomes based on clinical and pathological characteristics. While most tumors in this category are diffuse large B-cell lymphoma (DLBCL), the recognition...
Conclusion/Relevance: Aggressive B-cell lymphoma is a heterogeneous entity with disparate outcomes based on clinical and pathological characteristics. While most tumors in this category are diffuse large B-cell lymphoma (DLBCL), the recognition that some cases have high-grade morphology and frequently harbor MYC and BCL2 and/or BCL6...